# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
2024 Financial Guidance G1 today reaffirmed its full year 2024 revenue guidance. G1's guidance is based on current expecta...
G1 Therapeutics (NASDAQ:GTHX) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.1...
Needham analyst Gil Blum downgrades G1 Therapeutics (NASDAQ:GTHX) from Buy to Hold.
HC Wainwright & Co. analyst Edward White maintains G1 Therapeutics (NASDAQ:GTHX) with a Buy and lowers the price target ...